By: ABRS- Academic Team
Introduction
Across the clinical development landscape, competitive advantage is no longer defined solely by scientific innovation—it is increasingly shaped by how efficiently a study can be activated. The study startup phase, often perceived as operational groundwork, has evolved into a strategic lever that directly impacts timelines, costs, and overall trial success.
This shift is being driven by two defining industry dynamics. First, the growing complexity of clinical trials—spanning multiple geographies, regulatory frameworks, and increasingly intricate protocol designs—demands earlier alignment and more sophisticated execution from the outset. Second, persistent pressure to accelerate development timelines, while maintaining rigorous compliance and data integrity, has significantly reduced tolerance for inefficiencies during startup.
For sponsors and CRO leaders, this raises a critical question: how can organizations build startup models that are both agile and globally compliant?
Within this context, Functional Service Provider (FSP) models are gaining strategic relevance. By embedding specialized expertise and scalable resources early in the process, FSP approaches enable more consistent regulatory navigation, faster site activation, and stronger operational control—without compromising quality.
Reframing study startup is therefore not just an operational adjustment, but a strategic imperative. Organizations that optimize this phase are better positioned to mitigate downstream risk, control costs, and ultimately accelerate patient access to new therapies.
Navigating Regulatory Complexity at Study Startup
Study startup has evolved into one of the most strategically sensitive phases in clinical development, largely due to the increasing complexity of regulatory expectations across global markets. What was once a sequential activation process has now become a highly coordinated, multi-stakeholder effort where regulatory precision directly influences both timelines and execution quality.
In the European Union, this shift became particularly evident with the full implementation of the Clinical Trials Information System (CTIS), which became mandatory for all new clinical trial applications on January 31, 2023. By establishing a single-entry portal for submissions across EU member states, CTIS was designed to streamline and harmonize the approval process. However, in practice, it has also introduced new operational demands, requiring sponsors to ensure a higher level of completeness, consistency, and coordination at the time of submission (European Medicines Agency [EMA], 2023).
This evolution did not stop at system implementation. In June 2024, updated CTIS transparency rules came into effect, significantly reducing the flexibility sponsors previously had in deferring the publication of certain trial information. As a result, organizations must now make earlier and more strategic decisions regarding data disclosure, documentation readiness, and the protection of commercially confidential information. These requirements extend the scope of study startup beyond regulatory submission, positioning it as a critical point of alignment between clinical, regulatory, legal, and operational teams (EMA, 2024).
At the same time, regulatory complexity is not limited to formal requirements—it is amplified by operational realities. Differences in national interpretations, ethics committee processes, and local documentation standards continue to introduce variability in startup timelines, particularly in multi-country studies. Even within harmonized frameworks, execution remains uneven, requiring sponsors to adopt more adaptive and region-specific strategies.
From an industry perspective, these regulatory pressures are converging with broader operational challenges. In a 2025 industry interview, experts highlighted that delays in site activation are increasingly linked not only to regulatory submissions, but also to fragmented communication, prolonged contract negotiations, and insufficient alignment between stakeholders during early startup phases (Mallon & Studna, 2025). This reinforces the idea that regulatory complexity cannot be managed in isolation—it must be addressed as part of an integrated startup strategy.
For sponsors, this environment demands a fundamental shift in mindset. Regulatory strategy is no longer a downstream function—it must be embedded early in study design and planning. High-quality submissions, proactive cross-functional alignment, and localized expertise are now essential to maintaining momentum.
Within this context, Functional Service Provider (FSP) models offer a strategic advantage. By embedding specialized regulatory and operational expertise at the earliest stages, FSP structures enable more consistent navigation of regional requirements, improve submission quality, and reduce the risk of rework or delays. More importantly, they provide the scalability and flexibility needed to manage variability across countries without compromising compliance.
Ultimately, navigating regulatory complexity in study startup is no longer about meeting minimum requirements—it is about building a foundation for execution. Organizations that approach this phase strategically are better positioned to reduce uncertainty, control timelines, and deliver studies with greater efficiency and confidence.
Rethinking Site Selection and Feasibility as Strategic Drivers of Startup Success
If regulatory readiness sets the framework for study startup, site selection and feasibility determine whether that framework can translate into execution. For sponsors, this is no longer a routine operational checkpoint. It is a strategic decision point with direct implications for recruitment, startup speed, budget control, and overall study performance.
A central issue is that traditional feasibility processes often remain burdensome, repetitive, and insufficiently standardized. In a 2024 industry analysis published by WCG, site feasibility and startup are described as processes that can significantly affect timelines, costs, and study success, while feasibility questionnaires and pre-study site visits are characterized as inefficient and duplicative when they are not harmonized across stakeholders (WCG, 2024). This matters because the quality of startup depends not only on whether sites are identified quickly, but on whether they are assessed in a way that is realistic, scalable, and operationally sustainable.
The problem becomes even more serious when projected recruitment potential does not match actual site performance. A 2024 peer-reviewed study published in PLOS ONE examined how site selection strategies can be improved through real-world data modeling and found that machine learning models using historical recruitment and patient-level data outperformed common baseline approaches used to rank sites for future studies (Hulstaert et al., 2024). For sponsors and executive teams, this is a meaningful signal: reliance on conventional feasibility assumptions alone is becoming harder to justify when more predictive, evidence-based alternatives are available.
This point is especially relevant in an environment where protocol complexity continues to rise and target populations are often narrower, more fragmented, and harder to reach. Under those conditions, selecting the wrong sites is not simply a startup inefficiency; it can create downstream consequences across enrollment timelines, site amendments, and cost recovery. The feasibility conversation, therefore, has to move beyond site willingness to participate and toward a more disciplined evaluation of capability, patient access, competing trial burden, and execution readiness.
Another persistent friction point is the amount of redundancy imposed on sites during feasibility. In a 2025 interview published by Applied Clinical Trials during the SCRS Global Site Solutions Summit, Christine Senn noted that sites may receive multiple preliminary feasibility questionnaires from different CROs for the same trial opportunity, often without sponsors being fully aware of that duplication. She also argued that pre-populated site databases and more centralized site information could reduce repeated administrative burden and improve collaboration between sponsors, CROs, and sites (Senn & Studna, 2025). That observation is important because it highlights a structural weakness in current startup models: feasibility is often treated as a sponsor task rather than a shared ecosystem process.
For leadership teams, the broader implication is clear. Site selection should not be measured only by speed or by the number of activated sites. It should be measured by how effectively it predicts study delivery. A site that activates quickly but under-enrolls, struggles operationally, or requires repeated corrective support can erode the very efficiencies startup was meant to create.
This is where more mature operating models become increasingly valuable. An FSP approach can strengthen startup by embedding dedicated expertise in feasibility, site intelligence, and regional operations early in the planning process. Rather than relying on fragmented outreach and static questionnaires alone, sponsors can build a more integrated assessment model that combines local knowledge, historical site performance, and cross-functional startup coordination. In practice, this can support more realistic country strategies, better site prioritization, and stronger alignment between study design and field execution.
Ultimately, rethinking site selection and feasibility is not about adding more process. It is about improving decision quality at a stage where poor assumptions become expensive. Sponsors that treat feasibility as a strategic capability—rather than an administrative formality—are better positioned to reduce startup friction, improve enrollment predictability, and protect study timelines from the outset.
Contracts and Budget Negotiations as Persistent Startup Bottlenecks
Even when regulatory pathways and site selection strategies are well aligned, study startup timelines are frequently delayed during contract and budget negotiations. Unlike other phases, this stage remains highly variable across institutions, with differences in legal requirements, approval workflows, and financial expectations introducing friction that is difficult to standardize.
One of the core challenges is that contracting is often treated as an administrative step rather than a strategic function. In practice, delays are driven by prolonged negotiation cycles, misalignment on fair market value, and limited transparency between sponsors, CROs, and sites. These issues become more pronounced in multi-country studies, where variability across regions further complicates coordination and execution (Industry reports, 2024; SCRS insights, 2024)
From a site perspective, budget negotiations are not only operational but also financial sustainability decisions. Inadequate coverage of startup activities—such as training, patient pre-screening, and administrative workload—can lead to prolonged discussions and reduced site engagement. This creates a cycle where delays in contracting directly impact activation timelines and, ultimately, enrollment performance (Clinical operations analyses, 2024).
For sponsors and executive teams, the implication is clear: optimizing study startup requires addressing contractual processes with the same level of rigor as regulatory and operational planning. Faster approvals alone are not sufficient if agreements remain unresolved.
In this context, more structured operating models—such as Functional Service Provider (FSP) approaches—can help reduce variability by introducing standardized templates, dedicated negotiation expertise, and earlier alignment across stakeholders. By transforming contracts and budgets into a coordinated and proactive process, organizations can improve predictability and maintain greater control over clinical development timelines.
Conclusion:
Study startup is no longer a preparatory phase—it is a defining moment that sets the trajectory for the entire clinical trial. As regulatory complexity increases, feasibility becomes more data-driven, and contractual processes continue to challenge timelines, the ability to execute efficiently from the outset has become a clear differentiator for sponsors and CROs alike.
What emerges across these dimensions is a common theme: fragmentation. Whether in regulatory navigation, site selection, or contract negotiation, delays are rarely caused by a single issue—they are the result of disconnected processes, misaligned stakeholders, and insufficient early planning.
Addressing this requires more than incremental improvements. It calls for a more integrated, strategic approach to startup—one that prioritizes early alignment, leverages data for decision-making, and embeds operational expertise where it matters most.
In this evolving landscape, models such as Functional Service Provider (FSP) offer a practical path forward. By enabling consistency, scalability, and specialized support across critical startup functions, FSP approaches can help organizations reduce variability, improve predictability, and accelerate study activation without compromising quality or compliance.
Ultimately, organizations that rethink study startup as a strategic capability—not just an operational requirement—will be better positioned to control timelines, optimize resources, and bring therapies to patients faster.
